There have been some reports of necrosis at the injection site following receipt of the 23-valent pneumococcal vaccine, but the vaccine’s overall benefit-risk balance “remains favorable,&rdquo ...

September 7, 2010 — Guidelines have been updated for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults, according to a report in the September 3 issue of MMWR.Morbidity ...

Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide (“PPV”), H5N1 pandemic influenza (avian ...

23-valent pneumococcal polysaccharide vaccine (PPSV23; Merck). The indications and schedules for the vaccines vary. All four vaccines are approved for adults.

MORE. Politics. All Foreign Affairs Cross-strait ...

RAHWAY, N.J., October 16, 2024--Merck’s CAPVAXIVE (Pneumo. 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease ...

Based on national-level CDC data from 2018-2022, the serotypes covered by CAPVAXIVE are responsible for more cases of invasive pneumococcal disease (IPD) in adults compared to PCV20 (pneumococcal ...

A research team has evaluated the real-world impact of a community-based pneumococcal vaccination support program for older adults conducted in Sera ...

| Apr. 11, 2025 06:38 ...

RAHWAY, N.J., October 23, 2024--CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older ...